Founded in Portugal, NexThera Tech emerged with a clear mission: to give new hope to cancer patients who have exhausted all conventional treatment options. By combining artificial intelligence with clinical expertise, the start-up focuses on personalised therapy plans for patients with late-stage cancer, an area too often overlooked by standard care pathways.
Behind the venture is a team personally driven by the impact of cancer treatment failures, determined to bring change where it’s needed most.
In 2024, NexThera Tech joined the EIT Jumpstarter Health category, a turning point that accelerated both their vision and execution. The programme helped the team validate their business model, refine their go-to-market strategy, and connect with healthcare experts across Europe. João Rocha Gomes, co-founder of NexThera Tech, reflects: “The programme offered the structure and connections we needed to move forward with confidence.”
They didn’t just learn, they acted. During the programme, they conducted customer interviews, refined their roadmap, and laid out a path toward clinical validation.
At the heart of NexThera Tech is an AI-powered platform that predicts the most effective treatment options for advanced-stage cancer patients.
The system analyses genomic, proteomic, and clinical data, continuously learning and adapting. Unlike traditional approaches, NexThera focuses specifically on late-stage cases, offering personalised therapies when standard protocols no longer apply.
Through the support of EIT Jumpstarter and their growing network, NexThera Tech has built a functional prototype, formed partnerships with academic and healthcare institutions, and set the stage for upcoming pilot studies. They’ve also begun planning their regulatory path, including CE-marking and future market entry.
With their sights set on clinical validation in collaboration with oncology centres, the team is preparing for a 2026 market launch.
The impact? A new layer of treatment decisions driven by data—designed not just to extend survival, but to improve the quality of life during critical phases of cancer care.
The coming months will focus on validating NexThera Tech’s platform in clinical settings. Beyond that, they are working to secure certification and enter the market across Europe. With strong academic ties and a mission grounded in personal experience, their roadmap is both ambitious and focused.
NexThera Tech’s journey shows how science, empathy, and innovation can converge to address real, unmet needs. Curious how your idea could grow with EIT Jumpstarter?
Learn more about the EIT Jumpstarter programme.
Follow NexThera Tech:
Subscribe to Our Newsletter
European Pre-Acceleration Programme
Infopark 1 Building E, Neumann Janos utca, 1117, Budapest
Copyright EIT Jumpstarter © 2025 All Rights Reserved
